Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference


SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of reperfusion injury, today announced that management will present and participate in one-on-one investor meetings at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference, being held virtually, February 11-12, 2025.

See the original post:
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

Related Posts